{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T16:56:43Z","timestamp":1770742603721,"version":"3.49.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","award":["GSK study 213359"],"award-info":[{"award-number":["GSK study 213359"]}],"id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1136\/ijgc-2023-004605","type":"journal-article","created":{"date-parts":[[2023,11,6]],"date-time":"2023-11-06T07:15:16Z","timestamp":1699254916000},"page":"1733-1742","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Optimizing disease progression assessment using blinded central independent review and comparing it with investigator assessment in the PRIMA\/ENGOT-ov26\/GOG-3012 trial: challenges and solutions"],"prefix":"10.1016","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4584-8908","authenticated-orcid":false,"given":"Thomas J","family":"Herzog","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaun A","family":"Wahab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8085-1010","authenticated-orcid":false,"given":"Mansoor R","family":"Mirza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4578-2061","authenticated-orcid":false,"given":"Bhavana","family":"Pothuri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ignace","family":"Vergote","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Whitney S","family":"Graybill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Izabela A","family":"Malinowska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Whitney","family":"York","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean A","family":"Hurteau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Divya","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8376-9576","authenticated-orcid":false,"given":"Antonio","family":"Gonz\u00e1lez-Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6985-0159","authenticated-orcid":false,"given":"Bradley J","family":"Monk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1136\/ijgc-2023-004605_bb0010","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2023-004605_bb0015","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2023-004605_bb0020","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A phase 3 trial of bevacizumab in ovarian cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2023-004605_bb0025","doi-asserted-by":"crossref","first-page":"e374","DOI":"10.1016\/S1470-2045(22)00139-5","article-title":"Clinical research in ovarian cancer: consensus recommendations from the gynecologic cancer intergroup","volume":"23","author":"Vergote","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1136\/ijgc-2023-004605_bb0030","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.ygyno.2021.02.031","article-title":"The role of blinded independent radiologic review in ovarian cancer clinical trials: discerning the value","volume":"161","author":"Loreen","year":"2021","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-004605_bb0035","first-page":"308","article-title":"Ovarian cancer in focus: update on drugs in advanced ovarian cancer","volume":"18","author":"O\u2019Malley","year":"2020","journal-title":"Clin Adv Hematol Oncol"},{"key":"10.1136\/ijgc-2023-004605_bb0040","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ygyno.2017.08.012","article-title":"FDA ovarian cancer clinical trial endpoints workshop: a society of gynecologic oncology white paper","volume":"147","author":"Herzog","year":"2017","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-004605_bb0045","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1093\/annonc\/mdy514","article-title":"Exaggeration of PFS by blinded, independent, central review (BICR)","volume":"30","author":"Stone","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-2023-004605_bb0050","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.ejca.2008.10.031","article-title":"Lessons learned from independent central review","volume":"45","author":"Ford","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1136\/ijgc-2023-004605_bb0055","first-page":"34","article-title":"Ovarian cancer \u2014 difficulties in monitoring response","volume":"2","author":"King","year":"2015","journal-title":"Cancer Imaging"},{"key":"10.1136\/ijgc-2023-004605_bb0060","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in patients with newly diagnosed advanced ovarian cancer","volume":"381","author":"Gonz\u00e1lez-Mart\u00edn","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2023-004605_bb0065","author":"U.S.Food and Drug Administration","year":"2020","journal-title":"FDA approves niraparib for first-line maintenance of advanced ovarian cancer"},{"key":"10.1136\/ijgc-2023-004605_bb0070","author":"Agency","year":"2021","journal-title":"GSK: Niraparib summary of product characteristics"},{"key":"10.1136\/ijgc-2023-004605_bb0075","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1136\/ijgc-2023-004605_bb0080","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/IGC.0b013e3182070f17","article-title":"Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the gynecological cancer intergroup (GCIG)","volume":"21","author":"Rustin","year":"2011","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-2023-004605_bb0085","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ygyno.2014.11.074","article-title":"Progression-free survival by local investigator versus independent central review: comparative analysis of the AGO-Ovar16 trial","volume":"136","author":"Floquet","year":"2015","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-004605_bb0090","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1016\/j.ejca.2011.02.013","article-title":"Blinded independent central review of progression in cancer clinical trials: results from a meta-analysis","volume":"47","author":"Amit","year":"2011","journal-title":"Eur J Cancer"},{"key":"10.1136\/ijgc-2023-004605_bb0095","doi-asserted-by":"crossref","first-page":"3791","DOI":"10.1200\/JCO.2008.16.1711","article-title":"Blinded independent central review of progression-free survival in phase III clinical trials: important design element or unnecessary expense","volume":"26","author":"Dodd","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2023-004605_bb0100","first-page":"1","article-title":"Adjudication rates between readers in blinded independent central review of oncology studies","volume":"06","author":"Ford RON","year":"2016","journal-title":"J Clin Trials"},{"key":"10.1136\/ijgc-2023-004605_bb0105","author":"Kamavra","year":"2022","journal-title":"EP233\/#541 patterns of initial ovarian cancer recurrence on niraparib maintenance monotherapy in patients with no baseline evidence of disease following first-line chemotherapy: PRIMA\/ENGOT-ov26\/GOG-3012 post-hoc subgroup analysis"},{"key":"10.1136\/ijgc-2023-004605_bb0110","author":"Boccia","year":"2022","journal-title":"2022-RA-1414-ESGO pattern of recurrence and CA125 monitoring in BRCA wild-typerecurrent ovarian cancer patients under maintenance with niraparib"},{"key":"10.1136\/ijgc-2023-004605_bb0115","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ejca.2020.08.021","article-title":"Concordance between CA-125 and RECIST progression in patients with germline BRCA-mutated platinum-sensitive relapsed ovarian cancer treated in the Solo2 trial with olaparib as maintenance therapy after response to chemotherapy","volume":"139","author":"Tjokrowidjaja","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1136\/ijgc-2023-004605_bb0120","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1177\/0092861512459733","article-title":"Evaluation of blinded independent central review of tumor progression in oncology clinical trials: a meta-analysis","volume":"47","author":"Zhang","year":"2013","journal-title":"Ther Innov Regul Sci"},{"key":"10.1136\/ijgc-2023-004605_bb0125","article-title":"Meta-analysis of 49 roche oncology trials comparing blinded independent central review (BICR) and local evaluation to assess the value of BICR","author":"Lian","year":"2023","journal-title":"Oncologist"},{"key":"10.1136\/ijgc-2023-004605_bb0130","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-017240","article-title":"Systematic bias between blinded independent central review and local assessment: literature review and analyses of 76 phase III randomised controlled trials in 45 688 patients with advanced solid tumour","volume":"8","author":"Zhang","year":"2018","journal-title":"BMJ Open"},{"key":"10.1136\/ijgc-2023-004605_bb0135","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1093\/jnci\/92.18.1534","article-title":"Re: new guidelines to evaluate the response to treatment in solid tumors[ovarian cancer]","volume":"92","author":"Vergote","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1136\/ijgc-2023-004605_bb0140","doi-asserted-by":"crossref","first-page":"4849","DOI":"10.1007\/s00330-018-5389-z","article-title":"Radiomics of high-grade serous ovarian cancer: association between quantitative CT features, residual tumour and disease progression within 12 months","volume":"28","author":"Rizzo","year":"2018","journal-title":"Eur Radiol"},{"key":"10.1136\/ijgc-2023-004605_bb0145","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1007\/s00330-017-4779-y","article-title":"A novel representation of inter-site tumour heterogeneity from pre-treatment computed tomography textures classifies ovarian cancers by clinical outcome","volume":"27","author":"Vargas","year":"2017","journal-title":"Eur Radiol"},{"key":"10.1136\/ijgc-2023-004605_bb0150","doi-asserted-by":"crossref","first-page":"5370","DOI":"10.1007\/s00330-020-06937-z","article-title":"Early detection of ovarian cancer","volume":"30","author":"Forstner","year":"2020","journal-title":"Eur Radiol"},{"key":"10.1136\/ijgc-2023-004605_bb0155","article-title":"Clinical trial endpoints for the approval of cancer drugs and biologics","author":"U.S. Food and Drug Administration","year":"2018","journal-title":"Guidance for Industry"},{"key":"10.1136\/ijgc-2023-004605_bb0160","author":"European medicines agency","year":"2012","journal-title":"Appendix 1 to the guideline on the evaluation of anticancer medicinal products in man-methodological consideration for using progression-free survival (PFS) or disease-free survival (DFS) in Confirmatory trials"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24017778?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24017778?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ijgc-2023-004605","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T01:28:44Z","timestamp":1753234124000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X24017778"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":31,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S1048891X24017778"],"URL":"https:\/\/doi.org\/10.1136\/ijgc-2023-004605","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimizing disease progression assessment using blinded central independent review and comparing it with investigator assessment in the PRIMA\/ENGOT-ov26\/GOG-3012 trial: challenges and solutions","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ijgc-2023-004605","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, an indication of whether changes were made, and the use is non-commercial. See: http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/.","name":"copyright","label":"Copyright"}]}}